nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A5—Teniposide—lymphatic system cancer	0.142	0.214	CbGbCtD
Triazolam—CYP2C9—Teniposide—lymphatic system cancer	0.0954	0.143	CbGbCtD
Triazolam—CYP3A7—Vincristine—lymphatic system cancer	0.0913	0.137	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0913	0.137	CbGbCtD
Triazolam—CYP3A5—Vincristine—lymphatic system cancer	0.0685	0.103	CbGbCtD
Triazolam—CYP3A4—Cytarabine—lymphatic system cancer	0.0563	0.0846	CbGbCtD
Triazolam—CYP3A4—Teniposide—lymphatic system cancer	0.0555	0.0833	CbGbCtD
Triazolam—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0388	0.0583	CbGbCtD
Triazolam—CYP3A4—Vincristine—lymphatic system cancer	0.0267	0.0401	CbGbCtD
Triazolam—Hearing impaired—Fludarabine—lymphatic system cancer	0.0056	0.0168	CcSEcCtD
Triazolam—Jaundice—Mechlorethamine—lymphatic system cancer	0.00449	0.0135	CcSEcCtD
Triazolam—Sleep disorder—Fludarabine—lymphatic system cancer	0.00447	0.0134	CcSEcCtD
Triazolam—Aggression—Bleomycin—lymphatic system cancer	0.00445	0.0133	CcSEcCtD
Triazolam—Deafness—Fludarabine—lymphatic system cancer	0.00433	0.013	CcSEcCtD
Triazolam—Hepatic failure—Fludarabine—lymphatic system cancer	0.00431	0.0129	CcSEcCtD
Triazolam—Visual disturbance—Fludarabine—lymphatic system cancer	0.00409	0.0122	CcSEcCtD
Triazolam—Tinnitus—Mechlorethamine—lymphatic system cancer	0.00386	0.0115	CcSEcCtD
Triazolam—Thinking abnormal—Carmustine—lymphatic system cancer	0.00373	0.0112	CcSEcCtD
Triazolam—Coordination abnormal—Carmustine—lymphatic system cancer	0.00348	0.0104	CcSEcCtD
Triazolam—Stomatitis—Teniposide—lymphatic system cancer	0.00331	0.00992	CcSEcCtD
Triazolam—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.0033	0.00988	CcSEcCtD
Triazolam—Sweating increased—Fludarabine—lymphatic system cancer	0.00326	0.00977	CcSEcCtD
Triazolam—Disorientation—Bleomycin—lymphatic system cancer	0.00317	0.00951	CcSEcCtD
Triazolam—Dysuria—Fludarabine—lymphatic system cancer	0.00313	0.00938	CcSEcCtD
Triazolam—Mental disability—Carmustine—lymphatic system cancer	0.00296	0.00888	CcSEcCtD
Triazolam—Stomatitis—Fludarabine—lymphatic system cancer	0.00291	0.00872	CcSEcCtD
Triazolam—Anorexia—Mechlorethamine—lymphatic system cancer	0.0028	0.00839	CcSEcCtD
Triazolam—Deafness—Vincristine—lymphatic system cancer	0.00264	0.00792	CcSEcCtD
Triazolam—Amnesia—Carmustine—lymphatic system cancer	0.00264	0.0079	CcSEcCtD
Triazolam—Hepatic failure—Vincristine—lymphatic system cancer	0.00263	0.00789	CcSEcCtD
Triazolam—Visual impairment—Fludarabine—lymphatic system cancer	0.00258	0.00774	CcSEcCtD
Triazolam—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00255	0.00765	CcSEcCtD
Triazolam—Agitation—Teniposide—lymphatic system cancer	0.00244	0.00731	CcSEcCtD
Triazolam—Ataxia—Carmustine—lymphatic system cancer	0.00233	0.00698	CcSEcCtD
Triazolam—Hypertension—Teniposide—lymphatic system cancer	0.00229	0.00686	CcSEcCtD
Triazolam—Chest pain—Teniposide—lymphatic system cancer	0.00226	0.00677	CcSEcCtD
Triazolam—Urinary retention—Vincristine—lymphatic system cancer	0.00225	0.00674	CcSEcCtD
Triazolam—Ataxia—Vincristine—lymphatic system cancer	0.00222	0.00667	CcSEcCtD
Triazolam—Muscular weakness—Carmustine—lymphatic system cancer	0.00219	0.00655	CcSEcCtD
Triazolam—Confusional state—Teniposide—lymphatic system cancer	0.00218	0.00654	CcSEcCtD
Triazolam—Oedema—Teniposide—lymphatic system cancer	0.00217	0.00649	CcSEcCtD
Triazolam—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00216	0.00648	CcSEcCtD
Triazolam—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00216	0.00648	CcSEcCtD
Triazolam—Agitation—Fludarabine—lymphatic system cancer	0.00214	0.00642	CcSEcCtD
Triazolam—Stomatitis—Bleomycin—lymphatic system cancer	0.00213	0.00639	CcSEcCtD
Triazolam—Tachycardia—Teniposide—lymphatic system cancer	0.00211	0.00633	CcSEcCtD
Triazolam—Malaise—Fludarabine—lymphatic system cancer	0.0021	0.0063	CcSEcCtD
Triazolam—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00209	0.00627	CcSEcCtD
Triazolam—Muscular weakness—Vincristine—lymphatic system cancer	0.00209	0.00625	CcSEcCtD
Triazolam—Pruritus—Mechlorethamine—lymphatic system cancer	0.00208	0.00623	CcSEcCtD
Triazolam—Anorexia—Teniposide—lymphatic system cancer	0.00206	0.00618	CcSEcCtD
Triazolam—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00201	0.00602	CcSEcCtD
Triazolam—Discomfort—Fludarabine—lymphatic system cancer	0.00196	0.00588	CcSEcCtD
Triazolam—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00194	0.00581	CcSEcCtD
Triazolam—Dyspnoea—Teniposide—lymphatic system cancer	0.00193	0.00578	CcSEcCtD
Triazolam—Confusional state—Fludarabine—lymphatic system cancer	0.00192	0.00575	CcSEcCtD
Triazolam—Dysuria—Vincristine—lymphatic system cancer	0.00191	0.00573	CcSEcCtD
Triazolam—Oedema—Fludarabine—lymphatic system cancer	0.0019	0.0057	CcSEcCtD
Triazolam—Decreased appetite—Teniposide—lymphatic system cancer	0.00188	0.00564	CcSEcCtD
Triazolam—Vomiting—Mechlorethamine—lymphatic system cancer	0.00187	0.0056	CcSEcCtD
Triazolam—Stomatitis—Carmustine—lymphatic system cancer	0.00186	0.00558	CcSEcCtD
Triazolam—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00185	0.00554	CcSEcCtD
Triazolam—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00184	0.00551	CcSEcCtD
Triazolam—Anorexia—Fludarabine—lymphatic system cancer	0.00181	0.00544	CcSEcCtD
Triazolam—Feeling abnormal—Teniposide—lymphatic system cancer	0.00178	0.00535	CcSEcCtD
Triazolam—Stomatitis—Vincristine—lymphatic system cancer	0.00178	0.00532	CcSEcCtD
Triazolam—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00178	0.00532	CcSEcCtD
Triazolam—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00177	0.00531	CcSEcCtD
Triazolam—Nausea—Mechlorethamine—lymphatic system cancer	0.00174	0.00523	CcSEcCtD
Triazolam—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00173	0.00519	CcSEcCtD
Triazolam—Jaundice—Mitoxantrone—lymphatic system cancer	0.00173	0.00519	CcSEcCtD
Triazolam—Glossitis—Methotrexate—lymphatic system cancer	0.00172	0.00514	CcSEcCtD
Triazolam—Abdominal pain—Teniposide—lymphatic system cancer	0.00171	0.00513	CcSEcCtD
Triazolam—Erythema—Bleomycin—lymphatic system cancer	0.00171	0.00512	CcSEcCtD
Triazolam—Paraesthesia—Fludarabine—lymphatic system cancer	0.00171	0.00512	CcSEcCtD
Triazolam—Hallucination—Carmustine—lymphatic system cancer	0.00171	0.00511	CcSEcCtD
Triazolam—Dyspnoea—Fludarabine—lymphatic system cancer	0.0017	0.00508	CcSEcCtD
Triazolam—Dysarthria—Methotrexate—lymphatic system cancer	0.00167	0.00501	CcSEcCtD
Triazolam—Decreased appetite—Fludarabine—lymphatic system cancer	0.00165	0.00496	CcSEcCtD
Triazolam—Visual impairment—Carmustine—lymphatic system cancer	0.00165	0.00495	CcSEcCtD
Triazolam—Fatigue—Fludarabine—lymphatic system cancer	0.00164	0.00492	CcSEcCtD
Triazolam—Hallucination—Vincristine—lymphatic system cancer	0.00163	0.00488	CcSEcCtD
Triazolam—Constipation—Fludarabine—lymphatic system cancer	0.00163	0.00488	CcSEcCtD
Triazolam—Pain—Fludarabine—lymphatic system cancer	0.00163	0.00488	CcSEcCtD
Triazolam—Hypersensitivity—Teniposide—lymphatic system cancer	0.0016	0.00478	CcSEcCtD
Triazolam—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00159	0.00475	CcSEcCtD
Triazolam—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00157	0.0047	CcSEcCtD
Triazolam—Asthenia—Teniposide—lymphatic system cancer	0.00155	0.00466	CcSEcCtD
Triazolam—Malaise—Bleomycin—lymphatic system cancer	0.00154	0.00462	CcSEcCtD
Triazolam—Pruritus—Teniposide—lymphatic system cancer	0.00153	0.00459	CcSEcCtD
Triazolam—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00153	0.00458	CcSEcCtD
Triazolam—Erythema—Carmustine—lymphatic system cancer	0.00149	0.00447	CcSEcCtD
Triazolam—Diarrhoea—Teniposide—lymphatic system cancer	0.00148	0.00444	CcSEcCtD
Triazolam—Chest pain—Bleomycin—lymphatic system cancer	0.00146	0.00436	CcSEcCtD
Triazolam—Discomfort—Bleomycin—lymphatic system cancer	0.00144	0.00431	CcSEcCtD
Triazolam—Confusional state—Bleomycin—lymphatic system cancer	0.00141	0.00422	CcSEcCtD
Triazolam—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0014	0.0042	CcSEcCtD
Triazolam—Tremor—Carmustine—lymphatic system cancer	0.0014	0.00419	CcSEcCtD
Triazolam—Oedema—Bleomycin—lymphatic system cancer	0.0014	0.00418	CcSEcCtD
Triazolam—Erythema—Mitoxantrone—lymphatic system cancer	0.00139	0.00416	CcSEcCtD
Triazolam—Vomiting—Teniposide—lymphatic system cancer	0.00138	0.00413	CcSEcCtD
Triazolam—Agitation—Carmustine—lymphatic system cancer	0.00137	0.00411	CcSEcCtD
Triazolam—Asthenia—Fludarabine—lymphatic system cancer	0.00137	0.00409	CcSEcCtD
Triazolam—Dermatitis—Teniposide—lymphatic system cancer	0.00136	0.00409	CcSEcCtD
Triazolam—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00136	0.00407	CcSEcCtD
Triazolam—Headache—Teniposide—lymphatic system cancer	0.00136	0.00406	CcSEcCtD
Triazolam—Pruritus—Fludarabine—lymphatic system cancer	0.00135	0.00403	CcSEcCtD
Triazolam—Anorexia—Bleomycin—lymphatic system cancer	0.00133	0.00399	CcSEcCtD
Triazolam—Agitation—Vincristine—lymphatic system cancer	0.00131	0.00392	CcSEcCtD
Triazolam—Diarrhoea—Fludarabine—lymphatic system cancer	0.0013	0.0039	CcSEcCtD
Triazolam—Hypertension—Carmustine—lymphatic system cancer	0.00129	0.00386	CcSEcCtD
Triazolam—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00129	0.00386	CcSEcCtD
Triazolam—Nausea—Teniposide—lymphatic system cancer	0.00129	0.00385	CcSEcCtD
Triazolam—Hepatic failure—Methotrexate—lymphatic system cancer	0.00128	0.00383	CcSEcCtD
Triazolam—Chest pain—Carmustine—lymphatic system cancer	0.00127	0.00381	CcSEcCtD
Triazolam—Anxiety—Carmustine—lymphatic system cancer	0.00127	0.00379	CcSEcCtD
Triazolam—Paraesthesia—Bleomycin—lymphatic system cancer	0.00125	0.00375	CcSEcCtD
Triazolam—Malaise—Mitoxantrone—lymphatic system cancer	0.00125	0.00375	CcSEcCtD
Triazolam—Dyspnoea—Bleomycin—lymphatic system cancer	0.00124	0.00373	CcSEcCtD
Triazolam—Hypertension—Vincristine—lymphatic system cancer	0.00123	0.00369	CcSEcCtD
Triazolam—Confusional state—Carmustine—lymphatic system cancer	0.00123	0.00368	CcSEcCtD
Triazolam—Oedema—Carmustine—lymphatic system cancer	0.00122	0.00365	CcSEcCtD
Triazolam—Decreased appetite—Bleomycin—lymphatic system cancer	0.00121	0.00363	CcSEcCtD
Triazolam—Visual disturbance—Methotrexate—lymphatic system cancer	0.00121	0.00363	CcSEcCtD
Triazolam—Vomiting—Fludarabine—lymphatic system cancer	0.00121	0.00363	CcSEcCtD
Triazolam—Dermatitis—Fludarabine—lymphatic system cancer	0.0012	0.00359	CcSEcCtD
Triazolam—Hypertension—Mitoxantrone—lymphatic system cancer	0.0012	0.00359	CcSEcCtD
Triazolam—Pain—Bleomycin—lymphatic system cancer	0.00119	0.00358	CcSEcCtD
Triazolam—Headache—Fludarabine—lymphatic system cancer	0.00119	0.00357	CcSEcCtD
Triazolam—Tachycardia—Carmustine—lymphatic system cancer	0.00119	0.00356	CcSEcCtD
Triazolam—Chest pain—Mitoxantrone—lymphatic system cancer	0.00118	0.00354	CcSEcCtD
Triazolam—Anxiety—Mitoxantrone—lymphatic system cancer	0.00118	0.00353	CcSEcCtD
Triazolam—Discomfort—Mitoxantrone—lymphatic system cancer	0.00117	0.0035	CcSEcCtD
Triazolam—Oedema—Vincristine—lymphatic system cancer	0.00116	0.00348	CcSEcCtD
Triazolam—Anorexia—Carmustine—lymphatic system cancer	0.00116	0.00348	CcSEcCtD
Triazolam—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00115	0.00345	CcSEcCtD
Triazolam—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00115	0.00344	CcSEcCtD
Triazolam—Confusional state—Mitoxantrone—lymphatic system cancer	0.00114	0.00342	CcSEcCtD
Triazolam—Oedema—Mitoxantrone—lymphatic system cancer	0.00113	0.00339	CcSEcCtD
Triazolam—Nausea—Fludarabine—lymphatic system cancer	0.00113	0.00339	CcSEcCtD
Triazolam—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00112	0.00337	CcSEcCtD
Triazolam—Shock—Mitoxantrone—lymphatic system cancer	0.00111	0.00334	CcSEcCtD
Triazolam—Anorexia—Vincristine—lymphatic system cancer	0.00111	0.00332	CcSEcCtD
Triazolam—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00111	0.00331	CcSEcCtD
Triazolam—Insomnia—Carmustine—lymphatic system cancer	0.0011	0.0033	CcSEcCtD
Triazolam—Irritability—Methotrexate—lymphatic system cancer	0.0011	0.00328	CcSEcCtD
Triazolam—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00109	0.00328	CcSEcCtD
Triazolam—Paraesthesia—Carmustine—lymphatic system cancer	0.00109	0.00328	CcSEcCtD
Triazolam—Mood swings—Methotrexate—lymphatic system cancer	0.00109	0.00326	CcSEcCtD
Triazolam—Dyspnoea—Carmustine—lymphatic system cancer	0.00109	0.00325	CcSEcCtD
Triazolam—Somnolence—Carmustine—lymphatic system cancer	0.00108	0.00324	CcSEcCtD
Triazolam—Anorexia—Mitoxantrone—lymphatic system cancer	0.00108	0.00323	CcSEcCtD
Triazolam—Ataxia—Methotrexate—lymphatic system cancer	0.00108	0.00323	CcSEcCtD
Triazolam—Decreased appetite—Carmustine—lymphatic system cancer	0.00106	0.00317	CcSEcCtD
Triazolam—Insomnia—Vincristine—lymphatic system cancer	0.00105	0.00315	CcSEcCtD
Triazolam—Paraesthesia—Vincristine—lymphatic system cancer	0.00104	0.00313	CcSEcCtD
Triazolam—Pain—Carmustine—lymphatic system cancer	0.00104	0.00312	CcSEcCtD
Triazolam—Constipation—Carmustine—lymphatic system cancer	0.00104	0.00312	CcSEcCtD
Triazolam—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00103	0.00308	CcSEcCtD
Triazolam—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00102	0.00305	CcSEcCtD
Triazolam—Decreased appetite—Vincristine—lymphatic system cancer	0.00101	0.00303	CcSEcCtD
Triazolam—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00101	0.00302	CcSEcCtD
Triazolam—Somnolence—Mitoxantrone—lymphatic system cancer	0.00101	0.00302	CcSEcCtD
Triazolam—Feeling abnormal—Carmustine—lymphatic system cancer	0.001	0.00301	CcSEcCtD
Triazolam—Fatigue—Vincristine—lymphatic system cancer	0.001	0.003	CcSEcCtD
Triazolam—Asthenia—Bleomycin—lymphatic system cancer	0.001	0.003	CcSEcCtD
Triazolam—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000996	0.00298	CcSEcCtD
Triazolam—Constipation—Vincristine—lymphatic system cancer	0.000994	0.00298	CcSEcCtD
Triazolam—Pain—Vincristine—lymphatic system cancer	0.000994	0.00298	CcSEcCtD
Triazolam—Pruritus—Bleomycin—lymphatic system cancer	0.000987	0.00296	CcSEcCtD
Triazolam—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000984	0.00295	CcSEcCtD
Triazolam—Fatigue—Mitoxantrone—lymphatic system cancer	0.000976	0.00293	CcSEcCtD
Triazolam—Constipation—Mitoxantrone—lymphatic system cancer	0.000968	0.0029	CcSEcCtD
Triazolam—Pain—Mitoxantrone—lymphatic system cancer	0.000968	0.0029	CcSEcCtD
Triazolam—Abdominal pain—Carmustine—lymphatic system cancer	0.000963	0.00289	CcSEcCtD
Triazolam—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000951	0.00285	CcSEcCtD
Triazolam—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000933	0.0028	CcSEcCtD
Triazolam—Dysuria—Methotrexate—lymphatic system cancer	0.000928	0.00278	CcSEcCtD
Triazolam—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000926	0.00277	CcSEcCtD
Triazolam—Abdominal pain—Vincristine—lymphatic system cancer	0.000919	0.00275	CcSEcCtD
Triazolam—Hypersensitivity—Carmustine—lymphatic system cancer	0.000897	0.00269	CcSEcCtD
Triazolam—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000895	0.00268	CcSEcCtD
Triazolam—Vomiting—Bleomycin—lymphatic system cancer	0.000887	0.00266	CcSEcCtD
Triazolam—Drowsiness—Methotrexate—lymphatic system cancer	0.000885	0.00265	CcSEcCtD
Triazolam—Dermatitis—Bleomycin—lymphatic system cancer	0.000879	0.00263	CcSEcCtD
Triazolam—Asthenia—Carmustine—lymphatic system cancer	0.000874	0.00262	CcSEcCtD
Triazolam—Stomatitis—Methotrexate—lymphatic system cancer	0.000862	0.00258	CcSEcCtD
Triazolam—Hypersensitivity—Vincristine—lymphatic system cancer	0.000857	0.00257	CcSEcCtD
Triazolam—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000834	0.0025	CcSEcCtD
Triazolam—Asthenia—Vincristine—lymphatic system cancer	0.000834	0.0025	CcSEcCtD
Triazolam—Diarrhoea—Carmustine—lymphatic system cancer	0.000833	0.0025	CcSEcCtD
Triazolam—Nausea—Bleomycin—lymphatic system cancer	0.000829	0.00248	CcSEcCtD
Triazolam—Asthenia—Mitoxantrone—lymphatic system cancer	0.000813	0.00243	CcSEcCtD
Triazolam—Dizziness—Carmustine—lymphatic system cancer	0.000806	0.00241	CcSEcCtD
Triazolam—Diarrhoea—Vincristine—lymphatic system cancer	0.000796	0.00238	CcSEcCtD
Triazolam—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000775	0.00232	CcSEcCtD
Triazolam—Vomiting—Carmustine—lymphatic system cancer	0.000775	0.00232	CcSEcCtD
Triazolam—Dizziness—Vincristine—lymphatic system cancer	0.000769	0.0023	CcSEcCtD
Triazolam—Dermatitis—Carmustine—lymphatic system cancer	0.000767	0.0023	CcSEcCtD
Triazolam—Visual impairment—Methotrexate—lymphatic system cancer	0.000765	0.00229	CcSEcCtD
Triazolam—Headache—Carmustine—lymphatic system cancer	0.000763	0.00229	CcSEcCtD
Triazolam—Tinnitus—Methotrexate—lymphatic system cancer	0.00074	0.00222	CcSEcCtD
Triazolam—Vomiting—Vincristine—lymphatic system cancer	0.000739	0.00222	CcSEcCtD
Triazolam—Dermatitis—Vincristine—lymphatic system cancer	0.000733	0.00219	CcSEcCtD
Triazolam—Headache—Vincristine—lymphatic system cancer	0.000728	0.00218	CcSEcCtD
Triazolam—Nausea—Carmustine—lymphatic system cancer	0.000724	0.00217	CcSEcCtD
Triazolam—Vomiting—Mitoxantrone—lymphatic system cancer	0.00072	0.00216	CcSEcCtD
Triazolam—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000713	0.00214	CcSEcCtD
Triazolam—Headache—Mitoxantrone—lymphatic system cancer	0.000709	0.00213	CcSEcCtD
Triazolam—Erythema—Methotrexate—lymphatic system cancer	0.000691	0.00207	CcSEcCtD
Triazolam—Nausea—Vincristine—lymphatic system cancer	0.000691	0.00207	CcSEcCtD
Triazolam—Dysgeusia—Methotrexate—lymphatic system cancer	0.000677	0.00203	CcSEcCtD
Triazolam—Nausea—Mitoxantrone—lymphatic system cancer	0.000673	0.00202	CcSEcCtD
Triazolam—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000641	0.00192	CcSEcCtD
Triazolam—Malaise—Methotrexate—lymphatic system cancer	0.000623	0.00187	CcSEcCtD
Triazolam—Chest pain—Methotrexate—lymphatic system cancer	0.000589	0.00176	CcSEcCtD
Triazolam—Discomfort—Methotrexate—lymphatic system cancer	0.000582	0.00174	CcSEcCtD
Triazolam—Confusional state—Methotrexate—lymphatic system cancer	0.000569	0.0017	CcSEcCtD
Triazolam—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000545	0.00163	CcSEcCtD
Triazolam—Anorexia—Methotrexate—lymphatic system cancer	0.000538	0.00161	CcSEcCtD
Triazolam—Insomnia—Methotrexate—lymphatic system cancer	0.00051	0.00153	CcSEcCtD
Triazolam—Paraesthesia—Methotrexate—lymphatic system cancer	0.000507	0.00152	CcSEcCtD
Triazolam—Dyspnoea—Methotrexate—lymphatic system cancer	0.000503	0.00151	CcSEcCtD
Triazolam—Somnolence—Methotrexate—lymphatic system cancer	0.000502	0.0015	CcSEcCtD
Triazolam—Decreased appetite—Methotrexate—lymphatic system cancer	0.00049	0.00147	CcSEcCtD
Triazolam—Fatigue—Methotrexate—lymphatic system cancer	0.000486	0.00146	CcSEcCtD
Triazolam—Pain—Methotrexate—lymphatic system cancer	0.000483	0.00145	CcSEcCtD
Triazolam—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000465	0.00139	CcSEcCtD
Triazolam—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000461	0.00138	CcSEcCtD
Triazolam—Abdominal pain—Methotrexate—lymphatic system cancer	0.000446	0.00134	CcSEcCtD
Triazolam—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000416	0.00125	CcSEcCtD
Triazolam—Asthenia—Methotrexate—lymphatic system cancer	0.000405	0.00121	CcSEcCtD
Triazolam—Pruritus—Methotrexate—lymphatic system cancer	0.000399	0.0012	CcSEcCtD
Triazolam—Diarrhoea—Methotrexate—lymphatic system cancer	0.000386	0.00116	CcSEcCtD
Triazolam—Dizziness—Methotrexate—lymphatic system cancer	0.000373	0.00112	CcSEcCtD
Triazolam—Vomiting—Methotrexate—lymphatic system cancer	0.000359	0.00107	CcSEcCtD
Triazolam—Dermatitis—Methotrexate—lymphatic system cancer	0.000355	0.00106	CcSEcCtD
Triazolam—Headache—Methotrexate—lymphatic system cancer	0.000353	0.00106	CcSEcCtD
Triazolam—Nausea—Methotrexate—lymphatic system cancer	0.000335	0.001	CcSEcCtD
